Skip to main content

23andMe announces $300M deal for your DNA with giant drug company GSK

23andMe will soon be doing a lot more with the gene information it has been collecting — and turning your DNA data into dollar bills.

The home genetics company has teamed up with pharmaceutical giant GlaxoSmithKline (GSK) to design new drugs that could treat diseases like Parkinson’s, among others. Given 23andMe’s substantial genetic database provided by its 5 million customers, the company hopes that a partnership with GSK could provide the necessary data to develop effective therapies.

Recommended Videos

“Since the inception of 23andMe, our mission has been to help people access, understand and benefit from the human genome,” Anne Wojcicki, the company’s CEO and co-founder, said in a statement. “Today, I am thrilled to announce that we are launching a collaboration with GlaxoSmithKline to accelerate our ability to make those novel treatments and cures a reality.”

This collaboration also involves DNA the company’s has collected from millions of people — and hundreds of millions of dollars. GSK made a $300 million investment in 23andMe as part of the partnership; the pharmaceutical giant will maintain exclusive rights to collaborate with 23andMe in order to develop drugs.

“By working with GSK, we believe we will accelerate the development of breakthroughs,” Wojcicki said. “Our genetic research — powered by millions of customers who have agreed to contribute — combined with GSK’s expertise in drug discovery and development, gives us the best chance for success.”

This collaboration marks the largest such effort to date in the home genetics testing space and hopes to leverage the bevy of data that companies like 23andMe and others have collected thanks to mail-in saliva tests. 23andMe is by far the most popular of these kits, which means it likely has the most to offer a pharmaceutical partner.

23andMe has said that they will ask customers whether they would like to participate in research before using their data, ensuring that adequate consent is attained in the process. “As always, if our customers do not want to participate in research, they can choose to opt out at any time,” Wojcicki wrote.

it was unclear whether the company would contact older customers about inclusion.

This isn’t the first time 23andMe has attempted to utilize its genetic data for scientific purposes. As Wojcicki noted, the research team at the company has published more than 100 scientific papers, and in 2015, the team launched 23andMe Therapeutics “to develop novel treatments and cures based on genetic insights from the consented 23andMe community.” Of course, with the help of GSK, these treatments and cures are likely to go much further.

Lulu Chang
Fascinated by the effects of technology on human interaction, Lulu believes that if her parents can use your new app…
Sebastian Stan lays out Bucky’s future after Thunderbolts
Sebastian Stan in Thunderbolts.

There are some spoilers ahead for the ending of Marvel's Thunderbolts. Stop reading now if you don't want to be spoiled.

Earlier this year, Captain America: Brave New World briefly introduced a new direction for James "Bucky" Barnes, a character Sebastian Stan has been playing since 2011 in Captain America: The First Avenger. In Brave New World, the former Winter Soldier apparently retired from being a reformed hero and went into politics by running for Congress. Thunderbolts reveals that Bucky won his election to the House of Representatives. But his stay in Congress was short.

Read more
Jeep Compass EV breaks cover—but will it come to the U.S.?
jeep compass ev us newjeepcompassfirsteditionhawaii  4

Jeep just pulled the wraps off the all-new Compass EV, and while it’s an exciting leap into the electric future, there's a catch—it might not make it to the U.S. anytime soon.
This is a brand new electric version of the Jeep Compass, and being built on Stellantis' STLA platform—the same architecture underpinning models like the Peugeot E-3008 and E-5008—it looks much slicker and packs a lot more inside than previous versions of the Compass.
Let’s start with what’s cool: the new Compass EV is packing up to 404 miles of range on a single charge, a 74 kWh battery, and fast-charging that gets you from 20% to 80% in about 30 minutes. Not bad for a compact SUV with Jeep's badge on the nose.
There are two versions: a front-wheel-drive model with 213 horsepower and a beefier all-wheel-drive version with 375 horsepower. That AWD setup isn’t just for looks—it can handle 20% inclines even without front traction, and comes with extra ground clearance and better off-road angles. In short, it’s still a Jeep.
The design's been refreshed too, and inside you’ll find the kind of tech and comfort you’d expect in a modern EV—sleek, smart, and ready for both city streets and dirt trails.
But here’s the thing: even though production starts soon in Italy, Jeep hasn’t said whether the Compass EV is coming to America. And the signs aren’t promising.
Plans to build it in Canada were recently put on hold, with production now delayed until at least early 2026. Some of that might have to do with possible U.S. tariffs on Canadian and Mexican vehicles—adding a layer of uncertainty to the whole rollout.
According to Kelley Blue Book, a Stellantis spokesperson confirmed that the company has “temporarily paused work on the next-generation Jeep Compass, including activities at” the Canadian plant that was originally meant to build the model. They added that Stellantis is “reassessing its product strategy in North America” to better match customer needs and demand for different powertrain options.
So while Europe and other markets are gearing up to get the Compass EV soon, American drivers might be left waiting—or miss out entirely.
That’s a shame, because on paper, this electric Jeep hits a lot of sweet spots. Let’s just hope it finds a way over here.

Read more
Charlie Cox singles out his least favorite Daredevil: Born Again episode
Charlie Cox in Daredevil: Born Again.

Daredevil: Born Again season 1 was largely reconceived after the 2023 actor and writer strikes. Dario Scardapane -- a veteran of The Punisher series on Netflix -- was brought in to be the new showrunner and he made a lot of changes to the series that were well-received. However, there's one episode that Scardapane didn't really change at all, and it happens to be the least favorite episode of Daredevil: Born Again's leading man, Charlie Cox.

During an appearance on The Playlist, Cox noted that he wasn't very fond of the season's fifth episode, "With Interest," which was a largely standalone episode that featured his character, Matt Murdock, in a bank during a hostage crisis.

Read more